Overview

Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet

Status:
Completed
Trial end date:
2006-10-01
Target enrollment:
0
Participant gender:
All
Summary
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Tolterodine Tartrate
Criteria
Inclusion Criteria:

- Subjects with a diagnosis of overactive bladder.

Exclusion Criteria:

- Subjects with significant stress incontinence as determined by the investigator.

- Subjects with recurrent urinary tract infections defined as treated for UTI; 5 times
in the last year.